Therapies for multiple sclerosis: translational achievements and outstanding needs. by Haghikia, A, Hohlfeld, R, Gold, R, Fugger, L

Early multidisciplinary intensive-care therapy can improve outcome of severe anti-NMDA-receptor encephalitis presenting with extreme delta brush by Schneider R., Brüne M., Breuer TG., Börnke C., Gold R., Juckel G.

Get full text

Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient by Wurm, H, Attfield, K, Iversen, AK, Gold, R, Fugger, L, Haghikia, A

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy by Haghikia, A, Dendrou, C, Schneider, R, Grüter, T, Postert, T, Matzke, M, Stephanik, H, Fugger, L, Gold, R

Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS by Comi, G, Kappos, L, Palace, J, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Gold, R

Erratum: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study (Journal of Neuro... by Gold, R, Comi, G, Palace, J, Siever, A, Gottschalk, R, Bijarnia, M, Von Rosenstiel, P, Tomic, D, Kappos, L

Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. by Gold, R, Comi, G, Palace, J, Siever, A, Gottschalk, R, Bijarnia, M, von Rosenstiel, P, Tomic, D, Kappos, L

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study by Gold, R, Comi, G, Palace, J, Siever, A, Gottschalk, R, Bijarnia, M, Von Rosenstiel, P, Tomic, D, Kappos, L

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. by Gold, R, Comi, G, Palace, J, Siever, A, Gottschalk, R, Bijarnia, M, von Rosenstiel, P, Tomic, D, Kappos, L

The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? by Vermersch, P, Berger, T, Gold, R, Lukas, C, Rovira, A, Meesen, B, Chard, D, Comabella, M, Palace, J, Trojano, M

Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients by Gold, R, Kappos, L, Palace, J, Siever, A, Marrosu, M, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Comi, G

Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multic... by Kappos, L, Comi, G, Palace, J, Siever, A, Marrosu, M, Mehling, M, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Gold, R

The effectiveness of diversion programmes for offenders using Class A drugs: a systematic review and meta-analysis by Hayhurst, K, Leitner, M, Davis, L, Millar, T, Jones, A, Flentje, R, Hickman, M, Fazel, S, Mayet, S, King, C, Senior, J, Lennox, C, Gold, R, Shaw, J

Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. by Leite, M, Jones, M, Ströbel, P, Marx, A, Gold, R, Niks, E, Verschuuren, J, Berrih-Aknin, S, Scaravilli, F, Canelhas, A, Morgan, B, Vincent, A, Willcox, N

The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens. by Ströbel, P, Moritz, R, Leite, M, Willcox, N, Chuang, W, Gold, R, Nix, W, Schalke, B, Kiefer, R, Müller-Hermelink, H, Jaretzki, A, Newsom-Davis, J, Marx, A

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. by Leite, M, Ströbel, P, Jones, M, Micklem, K, Moritz, R, Gold, R, Niks, E, Berrih-Aknin, S, Scaravilli, F, Canelhas, A, Marx, A, Newsom-Davis, J, Willcox, N, Vincent, A

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis by Gregory, A, Kaur, G, Punwani, D, Felce, J, Davis, S, Fugger, L, Dendrou, C, Attfield, K, Haghikia, A, Lambert, L, Leach, O, Prömel, S, Gold, R, Xifara, D, McVean, G, Butter, F, Mann, M, Poschmann, G, Nielsen, F, Siegel, R, Bell, J

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. by Gregory, A, Dendrou, C, Attfield, K, Haghikia, A, Xifara, D, Butter, F, Poschmann, G, Kaur, G, Lambert, L, Leach, O, Prömel, S, Punwani, D, Felce, J, Davis, S, Gold, R, Nielsen, F, Siegel, R, Mann, M, Bell, J, McVean, G, Fugger, L

BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial by Torr, B, Jones, C, Kavanaugh, G, Hamill, M, Allen, S, Choi, S, Garrett, A, Valganon-Petrizan, M, MacMahon, S, Yuan, L, Way, R, Harder, H, Gold, R, Taylor, A, Gabe, R, Lucassen, A, Manchanda, R, Fallowfield, L, Jenkins, V, Gandhi, A, Evans, DG, George, A, Hubank, M, Kemp, Z

‘A good decision is the one that feels right for me’: codesign with patients to inform theoretical underpinning of a decision aid website by Kohut, K, Morton, K, Hurley, K, Turner, L, Dale, C, Eastbrook, S, Gold, R, Henwood, K, Patton, S, Punjabi, R, White, H, Young, C, Young, J, Bancroft, E, Barnett, L, Cable, S, Connolly, G, Coad, B, Forman, A, Hanson, H, Kavanaugh, G, Sahan, K, Snape, K, Torr, B, Way, R, Winchester, E, Youngs, A, Eccles, D, Foster, C